Invivyd Inc (IVVD)
2.43
+0.21
(+9.46%)
USD |
NASDAQ |
May 01, 16:00
2.43
0.00 (0.00%)
After-Hours: 20:00
Invivyd Cash from Investing (TTM): 280.68M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 280.68M |
| September 30, 2023 | 63.95M |
| June 30, 2023 | -172.02M |
| March 31, 2023 | -204.63M |
| December 31, 2022 | -230.67M |
| Date | Value |
|---|---|
| September 30, 2022 | 46.06M |
| June 30, 2022 | -1.728M |
| March 31, 2022 | -1.711M |
| December 31, 2021 | -50.71M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-230.67M
Minimum
Dec 2022
280.68M
Maximum
Dec 2023
-30.09M
Average
-1.728M
Median
Jun 2022
Cash from Investing (TTM) Benchmarks
| Vanda Pharmaceuticals Inc | -12.06M |
| Ardelyx Inc | -131.25M |
| Viking Therapeutics Inc | -641.08M |
| Stoke Therapeutics Inc | 105.95M |
| MAIA Biotechnology Inc | -- |